These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

253 related items for PubMed ID: 18204237

  • 1. Comparison of chromogranin A, insulin-like growth factor 1 and prostate-specific antigen serum markers in prostate adenocarcinoma and benign prostatic hyperplasia.
    Sciarra A, Gentile V, Monti S, Dattilo C, Autran Gomez A, Salciccia S, Pannunzi LP, Toscano V, Di Silverio F.
    Urol Int; 2008; 80(1):68-73. PubMed ID: 18204237
    [Abstract] [Full Text] [Related]

  • 2. Insulin-like growth factor 1, chromogranin A and prostate specific antigen serum levels in prostate cancer patients and controls.
    Marszalek M, Wachter J, Ponholzer A, Leitha T, Rauchenwald M, Madersbacher S.
    Eur Urol; 2005 Jul; 48(1):34-9. PubMed ID: 15967249
    [Abstract] [Full Text] [Related]

  • 3. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
    Trojan L, Bode C, Weiss C, Mayer D, Grobholz R, Alken P, Michel MS.
    Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Distribution of high chromogranin A serum levels in patients with nonmetastatic and metastatic prostate adenocarcinoma.
    Sciarra A, Di Silverio F, Autran AM, Salciccia S, Gentilucci A, Alfarone A, Gentile V.
    Urol Int; 2009 Feb; 82(2):147-51. PubMed ID: 19321999
    [Abstract] [Full Text] [Related]

  • 7. Clinical understaging in patients with prostate adenocarcinoma submitted to radical prostatectomy: predictive value of serum chromogranin A.
    Sciarra A, Voria G, Monti S, Mazzone L, Mariotti G, Pozza M, D'Eramo G, Silverio FD.
    Prostate; 2004 Mar 01; 58(4):421-8. PubMed ID: 14968443
    [Abstract] [Full Text] [Related]

  • 8. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ, Baxter RC.
    Clin Endocrinol (Oxf); 1997 Feb 01; 46(2):145-54. PubMed ID: 9135695
    [Abstract] [Full Text] [Related]

  • 9. Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA.
    Scorilas A, Plebani M, Mazza S, Basso D, Soosaipillai AR, Katsaros N, Pagano F, Diamandis EP.
    Prostate; 2003 Feb 15; 54(3):220-9. PubMed ID: 12518327
    [Abstract] [Full Text] [Related]

  • 10. The chromogranin-A (CgA) in prostate cancer.
    Ranno S, Motta M, Rampello E, Risino C, Bennati E, Malaguarnera M.
    Arch Gerontol Geriatr; 2006 Feb 15; 43(1):117-26. PubMed ID: 16280180
    [Abstract] [Full Text] [Related]

  • 11. [Combined assay of serum prostate specific antigen and chromogranin A helps diagnosis of prostate cancer].
    Sun CC, Zheng W, Kong CZ, Wang X, Yang CM.
    Zhonghua Nan Ke Xue; 2006 Oct 15; 12(10):904-5, 909. PubMed ID: 17121020
    [Abstract] [Full Text] [Related]

  • 12. The prognostic value of serum chromogranin A and prostate specific antigen in prostate cancer patients for progression to the hormone resistance state.
    Zissimopoulos A, Bantis A, Sountoulides P, Giannakopoulos S, Kalaitzis C, Agelonidou E, Touloupidis S.
    Hell J Nucl Med; 2009 Oct 15; 12(3):234-7. PubMed ID: 19936334
    [Abstract] [Full Text] [Related]

  • 13. Serum insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in localized, metastasized prostate cancer and benign prostatic hyperplasia.
    Aksoy Y, Aksoy H, Bakan E, Atmaca AF, Akçay F.
    Urol Int; 2004 Oct 15; 72(1):62-5. PubMed ID: 14730168
    [Abstract] [Full Text] [Related]

  • 14. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and prostate cancer: correlation with Gleason score.
    Correa LL, Neto LV, Lima GA, Gabrich R, Miranda LC, Gadelha MR.
    Int Braz J Urol; 2015 Oct 15; 41(1):110-5. PubMed ID: 25928516
    [Abstract] [Full Text] [Related]

  • 15. Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer.
    Miyata Y, Sakai H, Hayashi T, Kanetake H.
    Prostate; 2003 Feb 01; 54(2):125-32. PubMed ID: 12497585
    [Abstract] [Full Text] [Related]

  • 16. [Vascular endothelial growth factor and insulin-like-growth factors in prostate cancer. ].
    Trapeznikova MF, Shibaeva AN, Ianshin AA, Urenkov SB, Mironova OS, Kazantseva IA, Kushlinskiĭ NE.
    Urologiia; 2004 Feb 01; (1):17-21. PubMed ID: 15022438
    [Abstract] [Full Text] [Related]

  • 17. Correlation between age and Chromogranin A determination in prostate diseases.
    Mearini L, Zucchi A, Scarponi E, Nunzi E, Aglietti MC, Bini V, Porena M.
    Cancer Biomark; 2004 Feb 01; 10(3-4):117-23. PubMed ID: 22674297
    [Abstract] [Full Text] [Related]

  • 18. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
    Becker C, Piironen T, Pettersson K, Björk T, Wojno KJ, Oesterling JE, Lilja H.
    J Urol; 2000 Jan 01; 163(1):311-6. PubMed ID: 10604382
    [Abstract] [Full Text] [Related]

  • 19. [The role of prostate specific antigen in diagnosis of localized adenocarcinoma of the prostate. Nara Uro-Oncology Research Group].
    Hirao Y, Ozono S, Kagebayashi Y, Yoshi M, Tani Y, Uemura H, Momose H, Okajima E.
    Hinyokika Kiyo; 1996 Oct 01; 42(10):795-804. PubMed ID: 8951478
    [Abstract] [Full Text] [Related]

  • 20. [Changes of serum total PSA and free PSA in patients with prostate carcinoma and benign prostate hyperplasia].
    Gao ZW, Liu G, Sheng BW.
    Ai Zheng; 2004 Jun 01; 23(6):701-3. PubMed ID: 15191675
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.